Skip to main content
. 2020 Jul 31;10:12982. doi: 10.1038/s41598-020-70026-w

Figure 1.

Figure 1

Molecule structures evaluated in this study. (A) Palbociclib (CDK4/6) and (B) Afatinib (EGFR), (C) AZD2014 (targets mTOR1 and mTOR2), (D) RDEA119 (targets MEK1/2), (E) AZD4054 (targets endothelin A receptor). (F) AZD0530 (Src inhibitor). Images created with Mobile Molecular DataSheet (Molecular Materials Informatics, Inc., Montreal Canada).